Zimmer Biomet Q3 sales rise 3.7% constant currency; adjusted EPS steady at $1.90; full-year guidance raised.

Zimmer Biomet reported third quarter net sales of $2.063 billion, up 3.7% on a constant currency basis, with adjusted diluted earnings per share steady at $1.90 despite a 13.8% drop in reported EPS to $1.00. The company generated strong operating cash flow of $560 million and free cash flow of $372.4 million. Growth was driven by strong performance in hips, S.E.T., and technology-related product lines, supporting an upward revision of full-year 2026 sales and adjusted EPS guidance. Zimmer Biomet also highlighted strategic promotions, expanded robotics partnerships, and new product launches as part of its growth and innovation strategy.

Zimmer Biomet's stock is currently priced at USD 96.61 on Pluang, showing a slight decline of 0.46% in the past day. The company's market cap stands at $18.51 billion as of Nov 04, 2026 18:42 WIB.